Publications

Detailed Information

Phase II study of low-dose paclitaxel and cisplatin as a second-line therapy after 5-fluorouracil/platinum chemotherapy in gastric cancer

Cited 18 time in Web of Science Cited 20 time in Scopus
Authors

Lee, Keun-Wook; Kim, Jee Hyun; Yun, Tak; Song, Eun Kee; Na, Im Il; Shin, Hytinchoon; Oh, So Yeon; Choi, In Sil; Oh, Do-YounKim, Dong-WanIm, Seock-Ah; Kim, Tae-You; Lee, Jong Seok; Heo, Dae Seog; Bang, Yung-Jue; Kim, Noe Kyeong

Issue Date
2007-09
Publisher
대한의학회
Citation
Journal of Korean Medical Science, Vol.22 No.SUPPL., pp.S115-S121
Abstract
This study was performed to evaluate the efficacy and toxicity of low-dose paclitaxel/cisplatin chemotherapy in patients with metastatic or recurrent gastric cancer that had failed 5-fluorouracil/platinum-based chemotherapy. Thirty-two patients with documented progression on or within 6 months after discontinuing 5-fluorouracil/platinum-based chemotherapy were enrolled. As a second-line treatment, paclitaxel (145 mg/m(2)) and cisplatin (60 mg/m(2)) was administered on day 1 every 3 weeks, Among 32 patients enrolled, 8 (25%) responded partially to paclitaxel/cisplatin, 8 (25%) had stable disease, and 14 (44%) had progressive disease. Two patients (6%) were not evaluable. The median time to progression (TTP) and overall survival for all patients were 2.9 months and 9.1 months, respectively. The most common hematologic toxicity was anemia (47%). Grade 3 neutropenia developed in but no other grade 3/4 hematologic toxicity occurred. The most three patients (9%), common non-hematologic toxicities were emesis (31%) and peripheral neuropathy (38%). Three cases (9%) of grade 3/4 emesis and 2 cases (6%) of grade 3 peripheral neuropathy developed. In conclusion, low-dose paclitaxel and cisplatin chemotherapy showed moderate activity with favorable toxicity profiles. However, relatively short TTP of this regimen warrants the development of more effective paclitaxel-based regimens other than combination with cisplatin in these patients as second-line therapies.
ISSN
1011-8934
Language
English
URI
https://hdl.handle.net/10371/29485
DOI
https://doi.org/10.3346/jkms.2007.22.S.S115
Files in This Item:
There are no files associated with this item.
Appears in Collections:

Related Researcher

  • College of Medicine
  • Department of Medicine
Research Area DNA 손상 반응 타겟 물질의 면역조절 효과, Effect of DNA damage response target substances on immunomodulatory action, Efficacy and biomarker validation studies of targeted therapeutics, Resistance mechanisms according to targeted therapeutics, 표적 항암제 내성 기전 연구, 표적 항암제의 효과 검증 및 바이오마커 규명

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share